DAPADRIFT 5 mg Tablet contains Dapagliflozin 5 mg, an oral antidiabetic agent classified as an SGLT2 inhibitor (Sodium-Glucose Co-Transporter 2 inhibitor). It works by reducing glucose reabsorption in the kidneys, thereby increasing urinary glucose excretion and lowering blood sugar levels. It is used in the management of Type 2 Diabetes Mellitus (T2DM) and offers additional cardiovascular and renal benefits in eligible patients.

USES

• Treatment of Type 2 Diabetes Mellitus in adults

• May be used as:

  • Monotherapy when metformin is not appropriate

  • Add-on therapy with other antidiabetics (e.g., metformin, DPP-4 inhibitors, insulin)

• May help in:

  • Reducing the risk of hospitalization for heart failure

  • Slowing the progression of chronic kidney disease

BENEFITS

• Improves glycemic control via insulin-independent mechanism

• Reduces body weight due to calorie loss through urine

• Lowers blood pressure (mild effect)

• Low risk of hypoglycemia when not used with insulin or sulfonylureas

• Cardiovascular and renal protection in high-risk patients

• Convenient once-daily oral dose

???????

SIDE EFFECTS

Common Side Effects:

• Frequent urination

• Genital fungal infections (especially in females)

• Urinary tract infections

• Mild dehydration

• Nausea or stomach discomfort

Less Common / Serious Side Effects:

• Diabetic ketoacidosis (DKA) – rare but serious; requires prompt medical attention

• Dehydration and hypotension

• Hypoglycemia (more likely when combined with insulin or insulin secretagogues)

• Increased LDL cholesterol

• Allergic reactions (rash, itching)